New strategies in prostate cancer

• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Eder, Matthias [VerfasserIn]
• Verfasst von: Kopka, Klaus [VerfasserIn]
• Verfasst von: Babich, John W. [VerfasserIn]
• Verfasst von: Eisenhut, Michael [VerfasserIn]
• Titel: New strategies in prostate cancer
• Titelzusatz: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy
• Verf.angabe: Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut
• E-Jahr: 2016
• Jahr: January 2016
• Umfang: 8 S.
• Fussnoten: Gesehen am 02.09.2020
• Titel Quelle: Enthalten in: Clinical cancer research
• Ort Quelle: Philadelphia, Pa. [u.a.] : AACR, 1995
• Jahr Quelle: 2016
• Band/Heft Quelle: 22(2016), 1, Seite 9-15
• ISSN Quelle: 1557-3265
• DOI: doi:10.1158/1078-0432.CCR-15-0820
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1728603331

Abstract

Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable and novel therapeutic approaches for palliation and increase of survival are needed. In this article, we discuss the recent development for noninvasive detection of recurrent disease and therapy of mCRPC with corresponding PSMA-targeted radioligands. Clin Cancer Res; 22(1); 9-15. ©2016 AACR.